Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Lymphoma
Lymphoma
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib
monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in
combination with one of two different high dose methotrexate based regimens (methotrexate/
temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line
therapy in patients with newly diagnosed, treatment nave PCNSL (Part B)
monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in
combination with one of two different high dose methotrexate based regimens (methotrexate/
temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line
therapy in patients with newly diagnosed, treatment nave PCNSL (Part B)
Lymphoma
II
Merrell, Ryan
NCT04947319
VICCNEU2250